Exploring Predictive Biomarkers for ADC-Induced Pulmonary Toxicities: The Enhertu Experience

  • Overviewing biomarkers for ADC-Induced pulmonary toxicities
  • Defining responsibility by discussing who should lead clinical ADC sample-based translational research for safety
  • Addressing the gap between preclinical toxicity teams and clinical safety teams
  • Case study: Exploring ILD concerns in HER2- targeted ADCs – how are biomarkers in blood helping refine prediction and how can we monitor and treat ADC toxicities?